Targeted Delivery of siRNA Therapeutics to Malignant Tumors

Over the past 20 years, a diverse group of ligands targeting surface biomarkers or receptors has been identified with several investigated to target siRNA to tumors. Many approaches to developing tumor-homing peptides, RNA and DNA aptamers, and single-chain variable fragment antibodies by using phag...

Descripción completa

Detalles Bibliográficos
Autores principales: Leng, Qixin, Woodle, Martin C., Mixson, A. James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700508/
https://www.ncbi.nlm.nih.gov/pubmed/29218233
http://dx.doi.org/10.1155/2017/6971297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700508/
https://www.ncbi.nlm.nih.gov/pubmed/29218233
http://dx.doi.org/10.1155/2017/6971297

Ejemplares similares